Recursion Pharmaceuticals ( RXRX 3.12%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

This paper uses cross-sectional surveys of households over 2007–21 from Thailand’s Socio-Economic Expenditure Survey to ...

After eight years of renovation and anticipation, the museum reopens this weekend with a two-day public celebration; ahead of the long-awaited debut, Observer got an exclusive preview.

Unchecked artificial intelligence may soon outthink, outmaneuver, and eventually replace human beings — unless we impose real ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

B y any measure, there is an enormous number of programming languages. Some lists contain hundreds, while the Historical ...

A solid clinical win for a promising candidate helped jolt the stock a few months ago. And just last week, the company's ...

The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...